Quantification of monoamine oxidase B expression with 11C-SL25.1188 for imaging reactive astrocytes in patients with Alzheimer’s disease
Open Access
- 6 September 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (2) , 1222-1233
Abstract
Purpose Astrocyte reactivation can be assessed using positron emission tomography (PET) ligands targeting monoamine oxidase B (MAO-B). 11C-SL25.1188 binds reversibly to MAO-B, allowing precise density measurements, but requires invasive arterial sampling. This study aimed to develop a simplified, noninvasive method to quantify MAO-B with 11C-SL25.1188 PET in Alzheimer’s disease (AD). Methods Six patients with mild cognitive impairment (MCI), five patients with AD, and six healthy controls (HCs) underwent 11C-SL25.1188 PET scans. The distribution volume ratios (DVRs) were calculated and compared using two methods: the original multilinear reference tissue model (MRTMO) and the Logan plot. Changes in MAO-B densities, plasma glial fibrillary acidic protein (GFAP) levels, and abnormal protein aggregation were examined among subjects. Results A strong agreement was observed between the DVRs estimated using MRTMO and those obtained with the Logan plot (r2 = 0.89), with the cerebellar cortex used as the reference region. This region was selected based on its similar total distribution volume values and comparable MAO-B levels between patients with AD and HCs. Patients with MCI showed higher DVRs in the parietal cortex compared to those with moderate AD. Moreover, patients with moderate AD had higher plasma GFAP levels than HCs but similar levels to patients with MCI. Conclusion MAO-B density in patients with MCI/AD can be accurately estimated by calculating DVRs using a simplified quantification method that does not require arterial blood sampling. The estimated MAO-B density shows an increase that peaks at the MCI stage, suggesting early astrocyte reactivation in the progression of AD pathology.Keywords
Funding Information
- Japan Science and Technology Agency (JP22dk0207063)
- Japan Science and Technology Agency (JP19dm0207072)
- Japan Science and Technology Agency (JP22dk0207055)
- Japan Science and Technology Agency (JP21zf0127004)
- Japan Science and Technology Agency (JP24zf0127012)
- Ajinomoto Co., Inc. (Ajinomoto Co., Inc.)
This publication has 53 references indexed in Scilit:
- Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's DiseaseAnnals of Neurology, 2023
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Alzheimer's disease drug development pipeline: 2022Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022
- Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive DisorderJAMA Psychiatry, 2019
- Physiology of Astroglia2019
- The State of US Health, 1990-2016JAMA, 2018
- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach2018
- Radiosynthesis of [11C]SL25.1188 via [11C]CO2 fixation for imaging monoamine oxidase BJournal of Labelled Compounds and Radiopharmaceuticals, 2011
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- Validation of the geriatric depression scale-short form among inpatientsJournal of Clinical Psychology, 1994